# IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients

> **NCT06765005** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Mabgeek Biotech.Co.Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** MG-K10

## Key facts

- **NCT ID:** NCT06765005
- **Lead sponsor:** Shanghai Mabgeek Biotech.Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-19
- **Primary completion:** 2025-05
- **Final completion:** 2025-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06765005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06765005, "IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06765005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*